Mouse anti-Human BMP-7 Monoclonal Antibody | anti-BMP-7 antibody

Mouse Anti-Human BMP-7

Cat. Num. AAA690608

• Gene Names: BMP7; OP-1
• Reactivity: Human
• Purity: Protein G chromatography
• Synonyms: BMP-7; Monoclonal Antibody; Mouse Anti-Human BMP-7; Anti-human BMP-7/OP-1; anti-BMP-7 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2
• Purity/Purification: Protein G chromatography
• Form/Format: Lyophilized
• Sequence Length: 431

• Application Notes: ELISA: In a sandwich ELISA (assuming 100ul/well), when used as a capture antibody at a concentration of 2.0 - 4.0 ug/ml, this antibody will detect at least 100 pg/ml of recombinant human BMP-7/OP-1 when used in conjunction with compatible secondary reagents.
• Antibody Generation: Produced in mice using highly pure (>98%) recombinant human BMP-7/OP-1 as the immunizing antigen. This IgG1K antibody was purified from cell culture by Protein G affinity chromatography.
• Buffer: PBS, pH 7.2

Related Product Information for anti-BMP-7 antibody

TGF-beta family members are key modulators of cell proliferation, differentiation, matrix synthesis, and apoptosis. As implied by their name, BMPs initiate, promote, and regulate the development, growth and remodeling of bone and cartilage. In addition to this role, BMPs are also involved in prenatal development and postnatal growth, remodeling and maintenance of a variety of other tissues and organs. BMP-7, also known as osteogenic protein-1 or OP-1, is a potent bone inducing agent, which in the presence of appropriate osteoconductive carrier (e.g. collagen sponge or synthetic hydroxyapatite) can be used in the treatment of bone defects. A bone-graft substitute, called OP-1TM implant, made of recombinant human BMP-7 associated with bovine bone-derived collagen, has recently been approved by the FDA as a device for treating critical-size bone fractures. The potential use of BMP-7 in dental reconstructive surgeries is currently under investigation. Recombinant human BMP-7 is a 28.8 kDa homodimeric glycoprotein consisting of two 116 amino acid subunits, which correspond to amino acid residues 316 to 431 of the full-length BMP-7 precursor.

NCBI and Uniprot Product Information

• NCBI GI #: 4502427
• NCBI GeneID: 655
• NCBI Accession #: NP_001710.1
• NCBI GenBank Nucleotide #: NM_001719.2
• UniProt Accession #: P18075; Q9H512; Q9NTQ7
• Molecular Weight: 49,313 Da
• NCBI Official Full Name: bone morphogenetic protein 7
• NCBI Official Synonym Full Names: bone morphogenetic protein 7
• NCBI Official Symbol: BMP7
• NCBI Official Synonym Symbols: OP-1
• NCBI Protein Information: bone morphogenetic protein 7; osteogenic protein 1
• UniProt Protein Name: Bone morphogenetic protein 7
• UniProt Gene Name: BMP7
• UniProt Synonym Gene Names: OP1; BMP-7; OP-1
• UniProt Entry Name: BMP7_HUMAN

NCBI Description

The bone morphogenetic proteins (BMPs) are a family of secreted signaling molecules that can induce ectopic bone growth. Many BMPs are part of the transforming growth factor-beta (TGFB) superfamily. BMPs were originally identified by an ability of demineralized bone extract to induce endochondral osteogenesis in vivo in an extraskeletal site. Based on its expression early in embryogenesis, the BMP encoded by this gene has a proposed role in early development and possible bone inductive activity. [provided by RefSeq, Jul 2008]

Uniprot Description

Function: Induces cartilage and bone formation. May be the osteoinductive factor responsible for the phenomenon of epithelial osteogenesis. Plays a role in calcium regulation and bone homeostasis.

Subunit structure: Homodimer; disulfide-linked. Interacts with SOSTDC1. Interacts with TWSG1

By similarity. Ref.6

Subcellular location: Secreted.

Tissue specificity: Expressed in the kidney and bladder. Lower levels seen in the brain.

Developmental stage: Expressed in the developing eye, brain and ear during embryogenesis. Ref.7

Post-translational modification: Several N-termini starting at positions 293, 300, 315 and 316 have been identified by direct sequencing resulting in secretion of different mature forms (Ref.5).

Pharmaceutical use: Available under the name Osigraft (Stryker). Its use is indicated in the treatment of tibial non-union of at least 9 months duration, secondary to trauma, in skeletally mature patients, in cases where autograft has failed or is unfeasible.

Sequence similarities: Belongs to the TGF-beta family.